Logo image of AMRX

AMNEAL PHARMACEUTICALS INC (AMRX) Stock Fundamental Analysis

USA - NASDAQ:AMRX - US03168L1052 - Common Stock

9.92 USD
+0.05 (+0.51%)
Last: 10/17/2025, 5:14:33 PM
10.0673 USD
+0.15 (+1.48%)
After Hours: 10/17/2025, 5:14:33 PM
Fundamental Rating

5

Overall AMRX gets a fundamental rating of 5 out of 10. We evaluated AMRX against 195 industry peers in the Pharmaceuticals industry. AMRX has a medium profitability rating, but doesn't score so well on its financial health evaluation. AMRX scores decently on growth, while it is valued quite cheap. This could make an interesting combination.


Dividend Valuation Growth Profitability Health

Quickly go to:

6

1. Profitability

1.1 Basic Checks

In the past year AMRX was profitable.
AMRX had a positive operating cash flow in the past year.
In multiple years AMRX reported negative net income over the last 5 years.
In the past 5 years AMRX always reported a positive cash flow from operatings.
AMRX Yearly Net Income VS EBIT VS OCF VS FCFAMRX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200M -200M -400M

1.2 Ratios

Looking at the Return On Assets, with a value of 0.10%, AMRX is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
With an excellent Return On Invested Capital value of 11.52%, AMRX belongs to the best of the industry, outperforming 88.21% of the companies in the same industry.
AMRX had an Average Return On Invested Capital over the past 3 years of 7.98%. This is significantly below the industry average of 15.30%.
The 3 year average ROIC (7.98%) for AMRX is below the current ROIC(11.52%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROIC 11.52%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
AMRX Yearly ROA, ROE, ROICAMRX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200 -300 -400

1.3 Margins

AMRX has a Profit Margin of 0.12%. This is in the better half of the industry: AMRX outperforms 80.00% of its industry peers.
With an excellent Operating Margin value of 13.31%, AMRX belongs to the best of the industry, outperforming 84.62% of the companies in the same industry.
AMRX's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 37.67%, AMRX is in line with its industry, outperforming 58.97% of the companies in the same industry.
In the last couple of years the Gross Margin of AMRX has grown nicely.
Industry RankSector Rank
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
AMRX Yearly Profit, Operating, Gross MarginsAMRX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20 -20 40 -40 -60

More info and screens

3

2. Health

2.1 Basic Checks

With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), AMRX is creating some value.
The number of shares outstanding for AMRX has been reduced compared to 1 year ago.
Compared to 5 years ago, AMRX has more shares outstanding
Compared to 1 year ago, AMRX has an improved debt to assets ratio.
AMRX Yearly Shares OutstandingAMRX Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M 400M
AMRX Yearly Total Debt VS Total AssetsAMRX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

Based on the Altman-Z score of 1.66, we must say that AMRX is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of AMRX (1.66) is better than 62.05% of its industry peers.
AMRX has a debt to FCF ratio of 9.66. This is a negative value and a sign of low solvency as AMRX would need 9.66 years to pay back of all of its debts.
Looking at the Debt to FCF ratio, with a value of 9.66, AMRX is in the better half of the industry, outperforming 79.49% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Altman-Z 1.66
ROIC/WACC1.16
WACC9.92%
AMRX Yearly LT Debt VS Equity VS FCFAMRX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500M 1B 1.5B 2B 2.5B

2.3 Liquidity

A Current Ratio of 1.43 indicates that AMRX should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.43, AMRX is doing worse than 69.74% of the companies in the same industry.
A Quick Ratio of 0.88 indicates that AMRX may have some problems paying its short term obligations.
AMRX has a Quick ratio of 0.88. This is in the lower half of the industry: AMRX underperforms 77.95% of its industry peers.
Industry RankSector Rank
Current Ratio 1.43
Quick Ratio 0.88
AMRX Yearly Current Assets VS Current LiabilitesAMRX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 500M 1B 1.5B

More info and screens

5

3. Growth

3.1 Past

AMRX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 17.46%, which is quite good.
AMRX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 10.63% yearly.
The Revenue has grown by 16.73% in the past year. This is quite good.
The Revenue has been growing by 11.43% on average over the past years. This is quite good.
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%

3.2 Future

AMRX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 11.95% yearly.
AMRX is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 0.60% yearly.
EPS Next Y34.97%
EPS Next 2Y26.16%
EPS Next 3Y24.1%
EPS Next 5Y11.95%
Revenue Next Year8.28%
Revenue Next 2Y7.29%
Revenue Next 3Y7.67%
Revenue Next 5Y0.6%

3.3 Evolution

When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
AMRX Yearly Revenue VS EstimatesAMRX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
AMRX Yearly EPS VS EstimatesAMRX Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0.5 1

More info and screens

9

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 13.41, which indicates a correct valuation of AMRX.
Compared to the rest of the industry, the Price/Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 89.23% of the companies listed in the same industry.
AMRX's Price/Earnings ratio indicates a rather cheap valuation when compared to the S&P500 average which is at 27.40.
A Price/Forward Earnings ratio of 10.75 indicates a reasonable valuation of AMRX.
Compared to the rest of the industry, the Price/Forward Earnings ratio of AMRX indicates a rather cheap valuation: AMRX is cheaper than 85.13% of the companies listed in the same industry.
When comparing the Price/Forward Earnings ratio of AMRX to the average of the S&P500 Index (22.94), we can say AMRX is valued rather cheaply.
Industry RankSector Rank
PE 13.41
Fwd PE 10.75
AMRX Price Earnings VS Forward Price EarningsAMRX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30 40

4.2 Price Multiples

Based on the Enterprise Value to EBITDA ratio, AMRX is valued cheaper than 90.26% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, AMRX is valued cheaply inside the industry as 88.72% of the companies are valued more expensively.
Industry RankSector Rank
P/FCF 11.91
EV/EBITDA 8.42
AMRX Per share dataAMRX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 6 8

4.3 Compensation for Growth

AMRX's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
The decent profitability rating of AMRX may justify a higher PE ratio.
A more expensive valuation may be justified as AMRX's earnings are expected to grow with 24.10% in the coming years.
PEG (NY)0.38
PEG (5Y)1.26
EPS Next 2Y26.16%
EPS Next 3Y24.1%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AMRX!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AMNEAL PHARMACEUTICALS INC

NASDAQ:AMRX (10/17/2025, 5:14:33 PM)

After market: 10.0673 +0.15 (+1.48%)

9.92

+0.05 (+0.51%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)08-05 2025-08-05/bmo
Earnings (Next)10-30 2025-10-30/bmo
Inst Owners41.99%
Inst Owner Change0.92%
Ins Owners46.35%
Ins Owner Change-3.49%
Market Cap3.12B
Analysts82
Price Target12.24 (23.39%)
Short Float %3.24%
Short Ratio3.14
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)40.21%
Min EPS beat(2)40.06%
Max EPS beat(2)40.37%
EPS beat(4)3
Avg EPS beat(4)18.44%
Min EPS beat(4)-22.85%
Max EPS beat(4)40.37%
EPS beat(8)7
Avg EPS beat(8)29.41%
EPS beat(12)10
Avg EPS beat(12)26.58%
EPS beat(16)11
Avg EPS beat(16)18.46%
Revenue beat(2)0
Avg Revenue beat(2)-4.66%
Min Revenue beat(2)-4.71%
Max Revenue beat(2)-4.6%
Revenue beat(4)1
Avg Revenue beat(4)-2.31%
Min Revenue beat(4)-4.71%
Max Revenue beat(4)1.22%
Revenue beat(8)4
Avg Revenue beat(8)-0.35%
Revenue beat(12)7
Avg Revenue beat(12)0.09%
Revenue beat(16)8
Avg Revenue beat(16)-0.43%
PT rev (1m)0%
PT rev (3m)2.86%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-11.27%
EPS NY rev (1m)3.02%
EPS NY rev (3m)8.87%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-1.2%
Revenue NY rev (1m)-0.03%
Revenue NY rev (3m)-0.39%
Valuation
Industry RankSector Rank
PE 13.41
Fwd PE 10.75
P/S 1.09
P/FCF 11.91
P/OCF 8.87
P/B N/A
P/tB N/A
EV/EBITDA 8.42
EPS(TTM)0.74
EY7.46%
EPS(NY)0.92
Fwd EY9.31%
FCF(TTM)0.83
FCFY8.4%
OCF(TTM)1.12
OCFY11.27%
SpS9.08
BVpS-0.36
TBVpS-4.33
PEG (NY)0.38
PEG (5Y)1.26
Profitability
Industry RankSector Rank
ROA 0.1%
ROE N/A
ROCE 16.4%
ROIC 11.52%
ROICexc 11.84%
ROICexgc 23.31%
OM 13.31%
PM (TTM) 0.12%
GM 37.67%
FCFM 9.17%
ROA(3y)-3.06%
ROA(5y)-1.33%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)7.98%
ROIC(5y)6.53%
ROICexc(3y)8.26%
ROICexc(5y)6.86%
ROICexgc(3y)18.59%
ROICexgc(5y)15.87%
ROCE(3y)10.57%
ROCE(5y)8.54%
ROICexcg growth 3Y25.12%
ROICexcg growth 5YN/A
ROICexc growth 3Y27.15%
ROICexc growth 5YN/A
OM growth 3Y6.45%
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.15%
GM growth 5Y4.39%
F-Score7
Asset Turnover0.83
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF 9.66
Debt/EBITDA 3.99
Cap/Depr 36.48%
Cap/Sales 3.14%
Interest Coverage 1.59
Cash Conversion 56.16%
Profit Quality 7750.49%
Current Ratio 1.43
Quick Ratio 0.88
Altman-Z 1.66
F-Score7
WACC9.92%
ROIC/WACC1.16
Cap/Depr(3y)33.21%
Cap/Depr(5y)30.06%
Cap/Sales(3y)3.22%
Cap/Sales(5y)3.1%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.46%
EPS 3Y-11.61%
EPS 5Y10.63%
EPS Q2Q%56.25%
EPS Next Y34.97%
EPS Next 2Y26.16%
EPS Next 3Y24.1%
EPS Next 5Y11.95%
Revenue 1Y (TTM)16.73%
Revenue growth 3Y10.1%
Revenue growth 5Y11.43%
Sales Q2Q%3.24%
Revenue Next Year8.28%
Revenue Next 2Y7.29%
Revenue Next 3Y7.67%
Revenue Next 5Y0.6%
EBIT growth 1Y26.75%
EBIT growth 3Y17.2%
EBIT growth 5YN/A
EBIT Next Year13.13%
EBIT Next 3Y10.06%
EBIT Next 5Y3.87%
FCF growth 1Y129.81%
FCF growth 3Y5.18%
FCF growth 5YN/A
OCF growth 1Y76.74%
OCF growth 3Y6.86%
OCF growth 5Y180.48%